TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The objective of the study is to evaluate the effects of a follow on formula containing the human milk probiotic Lactobacillus fermentum on the incidence of infection in 6 months old infants.


Options:
A: Arm Label: No probiotics; Type: ACTIVE_COMPARATOR; Interventions: Other: Infant formula | Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Other: Infant formula | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): No probiotics | Intervention Type: OTHER; Name: Infant formula; Assigned to Arm(s): Probiotic
B: Intervention Type: DRUG; Name: Mixture of probiotic bacteria and prebiotic oligosaccharide; Assigned to Arm(s): N/A
C: Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus fermentum | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Follow on formula without probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus fermentum; Assigned to Arm(s): Probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Follow on formula without probiotics; Assigned to Arm(s): Control
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: low calcium milk of 180 ml | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: regular milk of 180 ml | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: regular milk of 180 ml + probiotics | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: regular milk of 180 ml + probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: low calcium milk of 180 ml; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: regular milk of 180 ml; Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: regular milk of 180 ml + probiotics; Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: regular milk of 180 ml + probiotics; Assigned to Arm(s): 4

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The objective of the study is to evaluate the effects of a follow on formula containing the human milk probiotic Lactobacillus fermentum on the incidence of infection in 6 months old infants.


Options:
A: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics
B: Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus fermentum | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Follow on formula without probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus fermentum; Assigned to Arm(s): Probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Follow on formula without probiotics; Assigned to Arm(s): Control
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Active 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus acidophilus NCFM | Arm Label: Active 2; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Combination of Lactobacillus acidophilus and Bifidobacterium lactis | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus acidophilus NCFM; Assigned to Arm(s): Active 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Combination of Lactobacillus acidophilus and Bifidobacterium lactis; Assigned to Arm(s): Active 2
D: Intervention Type: DRUG; Name: Mixture of probiotic bacteria and prebiotic oligosaccharide; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Forms of Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)
Brief Summary: The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease Modifying Therapy (DMT) who are randomized to one of two treatment arms: fingolimod vs. standard of care DMT.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
B: Arm Label: Atacicept 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 75 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Atacicept 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Atacicept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matched to atacicept | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 25 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 75 mg | Intervention Type: DRUG; Name: Atacicept; Assigned to Arm(s): Atacicept 150 mg | Intervention Type: DRUG; Name: Placebo matched to atacicept; Assigned to Arm(s): Placebo
C: Arm Label: Fingolimod; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Multiple Sclerosis Disease Modifying Treatments (MS DMTs); Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard MS DMTs | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod | Intervention Type: DRUG; Name: Standard MS DMTs; Assigned to Arm(s): Multiple Sclerosis Disease Modifying Treatments (MS DMTs)
D: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Forms of Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)
Brief Summary: The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease Modifying Therapy (DMT) who are randomized to one of two treatment arms: fingolimod vs. standard of care DMT.


Options:
A: Arm Label: Fingolimod 1.25 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 1.25 mg | Arm Label: Fingolimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod 0.5 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fingolimod 1.25 mg; Assigned to Arm(s): Fingolimod 1.25 mg | Intervention Type: DRUG; Name: Fingolimod 0.5 mg; Assigned to Arm(s): Fingolimod 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)
C: Arm Label: Fingolimod; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Multiple Sclerosis Disease Modifying Treatments (MS DMTs); Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard MS DMTs | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod | Intervention Type: DRUG; Name: Standard MS DMTs; Assigned to Arm(s): Multiple Sclerosis Disease Modifying Treatments (MS DMTs)
D: Arm Label: FTY720D 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: FTY720D 1.25 mg switch to 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): FTY720D 0.5 mg, FTY720D 1.25 mg switch to 0.5 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Forms of Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)
Brief Summary: The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease Modifying Therapy (DMT) who are randomized to one of two treatment arms: fingolimod vs. standard of care DMT.


Options:
A: Arm Label: Fingolimod; Type: EXPERIMENTAL; Interventions: Drug: Fingolimod | Arm Label: Multiple Sclerosis Disease Modifying Treatments (MS DMTs); Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard MS DMTs | Intervention Type: DRUG; Name: Fingolimod; Assigned to Arm(s): Fingolimod | Intervention Type: DRUG; Name: Standard MS DMTs; Assigned to Arm(s): Multiple Sclerosis Disease Modifying Treatments (MS DMTs)
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: peginterferon beta-1a, Drug: Rebif | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: peginterferon beta-1a, Drug: Rebif | Intervention Type: DRUG; Name: peginterferon beta-1a; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: DRUG; Name: Rebif; Assigned to Arm(s): Group 1, Group 2
C: Intervention Type: DRUG; Name: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody); Assigned to Arm(s): N/A
D: Arm Label: GA 40 mg / GA 40 mg; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate (GA) | Arm Label: Placebo / GA 40 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Glatiramer acetate (GA), Drug: Placebo | Intervention Type: DRUG; Name: Glatiramer acetate (GA); Assigned to Arm(s): GA 40 mg / GA 40 mg, Placebo / GA 40 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / GA 40 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective， Randomized， Open-label， Multicentric，phaseIII Clinical Trial Compared With PC and CEF100 Followed by Docetaxel as Adjuvant Chemotherapy Regimen for Chinese Primary Triple Negative Breast Cancer Patients
Brief Summary: Previous studies in Western country show that triple-negative breast cancer has aggressive clinical and pathological features compared with non-triple negative breast cancer, including onset at a young age, advanced clinical stage, high histologic and nuclear grade and more distant recurrence.

According to the characteristics of triple negative breast tumor, the TNBC patients can benefit neither from hormonal therapies nor from target therapies against Her2 receptors. The only systemic therapy currently available is chemotherapy, and prognosis remains poor. It becomes more and more important to investigate the sensitive chemotherapy regimen for triple negative patients.

Cisplatin-based regimen was active for the patients of lung cancer, colorectal cancer and ect. Triple negative breast cancer patients were more sensitive to platinum-based chemotherapy regimens according to the results of some retrospective studies.

The investigators hypothesized that paclitaxel combined with cisplatin is more sensitive to triple negative breast cancer compared with CEF followed by docetaxel.


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Trastuzumab, Drug: Pertuzumab | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trastuzumab, Drug: Pertuzumab, Drug: Paclitaxel | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Pertuzumab; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm B
B: Arm Label: EC-T; Type: ACTIVE_COMPARATOR; Interventions: Drug: EC-T | Arm Label: TP; Type: EXPERIMENTAL; Interventions: Drug: TP | Intervention Type: DRUG; Name: EC-T; Assigned to Arm(s): EC-T | Intervention Type: DRUG; Name: TP; Assigned to Arm(s): TP
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: nab-Paclitaxel, Drug: Gemcitabine | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: nab-Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: nab-Paclitaxel; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm B
D: Arm Label: 6 cycles of PC adjuvant chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Paclitaxel Cisplatin | Arm Label: 3 cycles of FEC followed by 3 cycles of Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T) | Intervention Type: DRUG; Name: Paclitaxel Cisplatin; Assigned to Arm(s): 6 cycles of PC adjuvant chemotherapy | Intervention Type: DRUG; Name: fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T); Assigned to Arm(s): 3 cycles of FEC followed by 3 cycles of Docetaxel

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Vestibular Rehabilitation on MS-related Fatigue and Upright Postural Control: a Randomized Controlled Trial
Brief Summary: The purpose of this study was to test the feasibility and effectiveness of a novel exercise intervention for individuals who live with multiple sclerosis (MS).


Options:
A: Arm Label: Task-oriented circuit class training; Type: EXPERIMENTAL; Interventions: Behavioral: Task-oriented circuit class training | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: Task-oriented circuit class training; Assigned to Arm(s): Task-oriented circuit class training | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): Usual Care
B: Arm Label: Exercise: Vestibular Rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Exercise: Vestibular Rehabilitation | Arm Label: Exercise Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Arm Label: Wait-listed Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise: Vestibular Rehabilitation; Assigned to Arm(s): Exercise: Vestibular Rehabilitation | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise Control
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Device: Body-weight supported treadmill, Device: Lokomat | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Device: Body-weight supported treadmill, Device: Lokomat | Intervention Type: DEVICE; Name: Body-weight supported treadmill; Assigned to Arm(s): Arm 1 | Intervention Type: DEVICE; Name: Lokomat; Assigned to Arm(s): Arm 1 | Intervention Type: DEVICE; Name: Body-weight supported treadmill; Assigned to Arm(s): Arm 2 | Intervention Type: DEVICE; Name: Lokomat; Assigned to Arm(s): Arm 2
D: Arm Label: Endurance training; Type: EXPERIMENTAL; Interventions: Behavioral: Endurance training, Behavioral: Standard care | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard care | Intervention Type: BEHAVIORAL; Name: Endurance training; Assigned to Arm(s): Endurance training | Intervention Type: BEHAVIORAL; Name: Standard care; Assigned to Arm(s): Endurance training, Standard care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effect of Adding Metoclopramide and Ondansetron to a Prophylactic Phenylephrine Infusion for the Management of Nausea and Vomiting Associated With Spinal Anesthesia for Cesarean Section
Brief Summary: The study investigates the incidence of intraoperative nausea and vomiting under spinal anesthesia using a phenylephrine infusion with and without prophylactic antiemetics.


Options:
A: Arm Label: Ginger; Type: EXPERIMENTAL; Interventions: Drug: Ginger | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Ginger; Assigned to Arm(s): Ginger | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
B: Arm Label: Exteriorization group; Type: OTHER; Interventions: Procedure: Repair of uterine incision, Procedure: Exteriorization of the uterus | Arm Label: Non exteriorization group; Type: OTHER; Interventions: Procedure: Repair of uterine incision, Procedure: Non exteriorization of the uterus | Intervention Type: PROCEDURE; Name: Repair of uterine incision; Assigned to Arm(s): Exteriorization group, Non exteriorization group | Intervention Type: PROCEDURE; Name: Exteriorization of the uterus; Assigned to Arm(s): Exteriorization group | Intervention Type: PROCEDURE; Name: Non exteriorization of the uterus; Assigned to Arm(s): Non exteriorization group
C: Arm Label: Phenylephrine bolus; Type: EXPERIMENTAL; Interventions: Drug: Phenylephrine bolus | Arm Label: Phenylephrine infusion; Type: EXPERIMENTAL; Interventions: Drug: phenylephrine infusion | Intervention Type: DRUG; Name: Phenylephrine bolus; Assigned to Arm(s): Phenylephrine bolus | Intervention Type: DRUG; Name: phenylephrine infusion; Assigned to Arm(s): Phenylephrine infusion
D: Arm Label: Metoclopramide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metoclopramide | Arm Label: Phenylephrine infusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Phenylephrine infusion | Arm Label: Combination Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Combination Group | Intervention Type: DRUG; Name: Metoclopramide; Assigned to Arm(s): Metoclopramide | Intervention Type: DRUG; Name: Phenylephrine infusion; Assigned to Arm(s): Phenylephrine infusion | Intervention Type: DRUG; Name: Combination Group; Assigned to Arm(s): Combination Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomach
Brief Summary: Patients with locally advanced resectable adenocarcinoma of the stomach or the esophagogastreal junction without previous therapy will be treated with one of two chemotherapy combinations before and after surgery. One half of the patients gets 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin and Docetaxel (FLOT), the others Epirubicin, Cisplatin and 5-FU (ECF). Main objective of the study is median overall survival.


Options:
A: Arm Label: S-1 plus cisplatin; Type: EXPERIMENTAL; Interventions: Drug: s-1 plus cisplatin | Arm Label: 5-Fu plus cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-Fu plus cisplatin | Intervention Type: DRUG; Name: s-1 plus cisplatin; Assigned to Arm(s): S-1 plus cisplatin | Intervention Type: DRUG; Name: 5-Fu plus cisplatin; Assigned to Arm(s): 5-Fu plus cisplatin
B: Intervention Type: DRUG; Name: Irinotecan; Assigned to Arm(s): N/A
C: Arm Label: FLOT; Type: EXPERIMENTAL; Interventions: Drug: 5-Fluorouracil, Drug: Leucovorin, Drug: Oxaliplatin, Drug: Docetaxel | Arm Label: ECF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Cisplatin, Drug: 5-fluorouracil | Intervention Type: DRUG; Name: 5-Fluorouracil; Assigned to Arm(s): FLOT | Intervention Type: DRUG; Name: Leucovorin; Assigned to Arm(s): FLOT | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): FLOT | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): FLOT | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): ECF | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): ECF | Intervention Type: DRUG; Name: 5-fluorouracil; Assigned to Arm(s): ECF
D: Arm Label: Trastuzumab emtansine; Type: EXPERIMENTAL; Interventions: Drug: Trastuzumab emtansine | Arm Label: Lapatinib + Capecitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lapatinib, Drug: Capecitabine | Intervention Type: DRUG; Name: Trastuzumab emtansine; Assigned to Arm(s): Trastuzumab emtansine | Intervention Type: DRUG; Name: Lapatinib; Assigned to Arm(s): Lapatinib + Capecitabine | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Lapatinib + Capecitabine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Self-management for Dual Sensory Impaired Older People and Their Caregivers: an Effective Approach?
Brief Summary: This study aims to determine the effectiveness of a self-management program for elderly with an acquired and concurrent hearing and visual impairment due to age-related disease processes.


Options:
A: Arm Label: Fall QI; Type: EXPERIMENTAL; Interventions: Behavioral: Falls QI | Arm Label: Connect & Falls QI; Type: EXPERIMENTAL; Interventions: Behavioral: Connect | Intervention Type: BEHAVIORAL; Name: Falls QI; Assigned to Arm(s): Fall QI | Intervention Type: BEHAVIORAL; Name: Connect; Assigned to Arm(s): Connect & Falls QI
B: Arm Label: Immediate INTERACT implementation; Type: EXPERIMENTAL; Interventions: Other: INTERACT Quality improvement program | Arm Label: Delayed intervention with reporting; Type: ACTIVE_COMPARATOR; Interventions: Other: Quarterly surveys/data reporting | Arm Label: Delayed intervention not reporting; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: INTERACT Quality improvement program; Assigned to Arm(s): Immediate INTERACT implementation | Intervention Type: OTHER; Name: Quarterly surveys/data reporting; Assigned to Arm(s): Delayed intervention with reporting
C: Arm Label: Self management; Type: EXPERIMENTAL; Interventions: Behavioral: Self management program | Intervention Type: BEHAVIORAL; Name: Self management program; Assigned to Arm(s): Self management | Intervention Type: BEHAVIORAL; Name: self management program; Assigned to Arm(s): Self management
D: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional Group; Type: EXPERIMENTAL; Interventions: Procedure: interprof ACT measures | Intervention Type: PROCEDURE; Name: interprof ACT measures; Assigned to Arm(s): Interventional Group

Answer: C